Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

2.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

428
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
428
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.

Allergy·2026
Same author

Comparison of Human Metapneumovirus- and Respiratory Syncytial Virus-Associated Health Burden in Adults With Chronic Underlying Health Conditions: A Global Systematic Review and Meta-analysis.

Open forum infectious diseases·2026
Same author

Investigating the gut microbiota in advanced heart failure and cardiac cachexia.

Gut microbes reports·2026
Same author

When the reliever becomes the risk.

Thorax·2026
Same author

Adverse outcomes in young adults with severe asthma: results from the UK Severe Asthma Registry.

ERJ open research·2026
Same author

The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.

Current obesity reports·2026

Related Experiment Video

Updated: Sep 9, 2025

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.5K

Pregnancy, asthma and exacerbations: a population-based cohort.

Bohee Lee1, Ernie Wong1, Tricia Tan2

  • 1National Heart and Lung Institute, Imperial College London, London, UK.

The European Respiratory Journal
|August 28, 2025
PubMed
Summary

Asthma exacerbations during pregnancy decreased overall, but hospitalizations rose. Reducing inhaled corticosteroid (ICS) use during pregnancy was a major, modifiable risk factor for asthma exacerbations.

More Related Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.8K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

880

Related Experiment Videos

Last Updated: Sep 9, 2025

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.5K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.8K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

880

Area of Science:

  • Reproductive medicine
  • Pulmonology
  • Public health

Background:

  • Asthma exacerbations in pregnancy pose risks to mothers and newborns.
  • Identifying modifiable risk factors is crucial for improving pregnancy outcomes.
  • This study focuses on inhaled corticosteroid (ICS) use as a key modifiable factor.

Purpose of the Study:

  • To analyze asthma exacerbation patterns during pregnancy.
  • To identify risk factors for exacerbations, emphasizing modifiable ones like ICS use.
  • To understand the impact of ICS reduction on asthma control in pregnant individuals.

Main Methods:

  • A UK-based cohort study (2004-2020) analyzed primary care and hospital data.
  • Pregnant women with asthma were identified, and exacerbations were defined by specific clinical events.
  • Multivariable logistic regression assessed associations between maternal factors, exacerbations, and ICS use.

Main Results:

  • Total asthma exacerbations decreased by ~30% during pregnancy, but hospital admission-related exacerbations increased 30-45% in trimesters 2 and 3.
  • 31% of women reduced their ICS prescriptions during pregnancy.
  • Reduced ICS use, a history of exacerbations, and high pre-pregnancy ICS+preventer prescriptions were significant risk factors for exacerbations.

Conclusions:

  • Hospitalization-associated asthma exacerbations increased during pregnancy despite an overall decline.
  • Reduced inhaled corticosteroid (ICS) use during pregnancy is a significant, modifiable risk factor for exacerbations.
  • Type-2 inflammation and suboptimal pre-pregnancy asthma control are other key risk factors.